Based on the positive expression of GHRH-R in the NB4, NB4-RAA, and K-562 cell lines used, we hypothesized that MIA-602 could be effective in overcoming APL resistance and serving as an adjuvant therapy in AML. This evidence concerns the gene GHRHR and acute promyelocytic leukemia.